AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

Statement of Changes in Beneficial Ownership

Initial Statement of Beneficial Ownership

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Richard A. Gonzalez	Executive Chairman Show All	Open Market Disposition (Sale)	-66.5K	-0.003765%	-12.96%	446.6K	$186.52 - $186.52	-$12.4M	07 Aug 2024	05 Aug 2024 - 05 Aug 2024
Richard A. Gonzalez	Executive Chairman Show All	Derivative Exercise and Sale (Sale)	-282.85K	-0.016017%	—	513.1K	$61.36 - $175	-$27.58M	19 Jul 2024	17 Jul 2024 - 17 Jul 2024
Susan E. Quaggin	Chief Scientific Officer and Director, Member of Scientific Advisory Board, Independnet Director Show All	Other Derivative Acquisition (Sale)	87	—	58.39%	236	$171.52 - $171.52	—	02 Jul 2024	30 Jun 2024 - 30 Jun 2024
Edward Joseph Rapp	Independent Director Show All	Other Derivative Acquisition (Sale)	225	—	0.87%	26.17K	$171.52 - $171.52	—	02 Jul 2024	30 Jun 2024 - 30 Jun 2024
Robert J. Alpern	Independent Director Show All	Other Derivative Acquisition (Sale)	43	—	0.45%	9.54K	$171.52 - $171.52	—	02 Jul 2024	30 Jun 2024 - 30 Jun 2024
Richard A. Gonzalez
Jennifer L. Davis
Susan E. Quaggin
Melody Boone Meyer
Rebecca B. Roberts
Brett J. Hart
Thomas Craig Freyman
Roxanne S. Austin
Robert J. Alpern
Edward Joseph Rapp
Frederick H. Waddell
Glenn F. Tilton
William H. L. Burnside
Susan E. Quaggin
Robert J. Alpern
Edward Joseph Rapp
Nicholas J. Donoghoe
Jeffrey Ryan Stewart
Jeffrey Ryan Stewart
Timothy J. Richmond
Timothy J. Richmond
Robert A. Michael
Robert A. Michael
Robert A. Michael
Scott T. Reents